公开(公告)号：WO2022063788A1

公开(公告)日：2022-03-31

申请号：PCT/EP2021/075965

申请日：2021-09-21

Applicant: ROTH, Johannes

Inventor： ROTH, Johannes

IPC: A61B18/14 ,  A61B18/00

Abstract: Die vorliegende Erfindung betrifft eine Schlinge zur hochfrequenz-chirurgischen Entfernung von krankhaftem Gewebe aus hohlen Körperorganen und zur Entfernung aller Arten von Fremdkörpern aus hohlen Körperorganen dadurch gekennzeichnet, dass die Schlinge aus zwei getrennten Hälften, einer ersten Schlingenhälfte (A) und einer zweiten Schlingenhälfte (B), besteht, wobei die erste (A) und die zweite Schlingenhälfte (B) durch Schließen dieser beiden Hälften zu einer komplett verbundenen Schlinge adaptierbar sind; und wobei sich an wenigstens einer Schlingenhälfte (A, B) zusätzlich eine Kamera (E) befindet, über die ein entsprechendes Kamerabild auf einen Monitor übertragen werden kann.

公开(公告)号：WO2003069349A2

公开(公告)日：2003-08-21

申请号：PCT/EP2003/001576

申请日：2003-02-17

Applicant: SORG, Clemens ,  ROTH, Johannes

Inventor： SORG, Clemens ,  ROTH, Johannes

IPC: G01N33/68

CPC classification number: G01N33/6872 ,  G01N2333/4727

Abstract: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker MRP8/MRP14, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of: (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex and/or nucleic acids encoding the polypeptide(s) present in said biological sample; and (c) comparing the amount and/or concentration of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex determined in said biological sample with the amount and/or concentration of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding MRP8 and/or MRP14 polypeptide(s) determined in said biological sample with the amount and/or concentration of nucleic acids encoding MRP8 and/or MRP14 polypeptide(s) measured in a control sample, wherein the difference in the amount of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex and/or nucleic acids encoding the polypeptide(s) is indicative for the stages of the disease to be diagnosed.

Abstract translation: 本发明涉及一种用于诊断基于标志物MRP8 / MRP14的炎性疾病的方法，特别是用于诊断炎性疾病的特定阶段和/或用于确定复发的风险和/或用于鉴别具有相似症状的疾病之间的所述方法 包括以下步骤：（a）获得要诊断的哺乳动物体液或组织的生物样品; （b）确定存在于所述生物样品中的MRP8和/或MRP14多肽和/或MRP8 / MRP14蛋白复合物和/或编码多肽的核酸的量和/或浓度; 和（c）将在所述生物样品中测定的MRP8和/或MRP14多肽和/或MRP8 / MRP14蛋白质复合物的量和/或浓度与MRP8和/或MRP14多肽的量和/或浓度进行比较 ）和/或MRP8 / MRP14蛋白复合物，和/或将编码所述生物样品中测定的MRP8和/或MRP14多肽的核酸的量和/或浓度与量和/或浓度 编码在对照样品中测量的MRP8和/或MRP14多肽的核酸，其中MRP8和/或MRP14多肽和/或MRP8 / MRP14多肽和/或编码 多肽指示要诊断的疾病的阶段。

公开(公告)号：WO2003069341A3

公开(公告)日：2003-08-21

申请号：PCT/EP2003/001575

申请日：2003-02-17

Applicant: SORG, Clemens ,  ROTH, Johannes

Inventor： SORG, Clemens ,  ROTH, Johannes

IPC: G01N33/564

Abstract: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or con­centration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measured in a control sample, wherein the difference in the amount of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide is indicative for the stages of the disease to be diagnosed.

公开(公告)号：WO2012143124A2

公开(公告)日：2012-10-26

申请号：PCT/EP2012/001670

申请日：2012-04-18

Applicant: ROTH + WEBER GMBH ,  ROTH, Johannes ,  ERMERT, Gerd

Inventor： ROTH, Johannes ,  ERMERT, Gerd

CPC classification number: H04N1/10 ,  H04N1/04 ,  H04N1/1903 ,  H04N1/1933 ,  H04N1/387 ,  H04N1/3876 ,  H04N2201/0456

Abstract: Die Erfindung betrifft ein großformatiges Scanner-System (1 ) mit wenigstens zwei kaskadenförmig angeordneten Bilderfassungselementen (2), wenigstens einer davor angeordneten Vorlagenträger, vorzugsweise eine Glasscheibe (3), sowie mit den wenigstens zwei kaskadenförmig angeordneten Bilderfassungselementen (2) gegenüber angeordneten, Reflektorwalzen (5), die mittels an den Seiten der Reflektorwalzen (5) angeordneter federnder Elemente (6) gegen die Glasscheibe (3) und/oder eine Scan-Vorlage (4) gedrückt werden. Erfindungsgemäß sind die Reflektorwalzen (5) an ihren Seitenbereichen (7) derart ausgebildet, dass sie nur außerhalb des Lesebereichs der Bilderfassungselemente (2) für die Scan-Vorlage (4) die Glasscheibe (3) berühren und dass die Scan-Vorlage (4) im Mittenbereich (8) der Reflektorwalzen (5) an der Glasscheibe (3) anliegt.

Abstract translation: 本发明涉及一种大幅面扫描仪系统（1）具有至少两个级联的图像感测元件（2），至少一个布置在所述文档支持的前面，优选地布置玻璃（3）的面板中，并用至少两个级联的图像感测元件（2）相反，镜面辊（ 5），其通过的装置，被布置（在所述反射器辊5）的弹性元件被压在玻璃板（3）和/或（4）的扫描模板（6）的侧面上。 根据本发明，在它们的侧部区域（7）的反射器辊子（5）被设计成使得它们只触摸图像感测元件（2），用于在扫描模板的读取范围外（4）的玻璃板（3），并且所述扫描模板（4） 在中心区域（8）的反射器辊（5）与玻璃板（3）。

公开(公告)号：WO2011117392A3

公开(公告)日：2011-09-29

申请号：PCT/EP2011/054630

申请日：2011-03-25

Applicant: UNIVERSITAETSKLINIKUM MUENSTER ,  EHRCHEN, Jan ,  VARGA, Georg ,  ROTH, Johannes ,  SUNDERKOETTER, Cord

Inventor： EHRCHEN, Jan ,  VARGA, Georg ,  ROTH, Johannes ,  SUNDERKOETTER, Cord

IPC: G01N33/50

Abstract: The present invention relates to a pharmaceutical composition comprising glucocorticoid (GC)-induced human monocytes, and optionally a pharmaceutically acceptable carrier. The present invention further relates to a pharmaceutical composition comprising GC and optionally a pharmaceutically acceptable carrier, for use in the treatment of a disease which is GC-responsive, wherein said pharmaceutical composition is to be administered to human monocytes ex vivo. The pharmaceutical composition may be used for treatment of a disease which is GC-responsive. In another aspect, the present invention relates to the use of GC for the preparation of a pharmaceutical composition for the treatment of a patient in need of a GC-therapy, wherein said GC is to be administered to monocytes of said patient ex vivo. In a further embodiment, the present invention relates to a method for the preparation of a pharmaceutical composition comprising the step of contacting human monocytes ex vivo with a GC. A teflon container (e.g. a teflon bag) comprising a glucocorticoid and optionally a colony-stimulating factor (CSF) is also envisaged. In an even further embodiment, the present invention relates to a method of screening for a compound which is suitable for the treatment of a GC-responsive disease, said method comprising: a) contacting a monocyte with a compound to be tested; b) evaluating whether the monocyte is GC-induced; and thereby, c) identifying compounds which are suitable for the treatment of a GC-responsive disease.

公开(公告)号：WO2003069349A3

公开(公告)日：2003-08-21

申请号：PCT/EP2003/001576

申请日：2003-02-17

Applicant: SORG, Clemens ,  ROTH, Johannes

Inventor： SORG, Clemens ,  ROTH, Johannes

IPC: G01N33/68

Abstract: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker MRP8/MRP14, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of: (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex and/or nucleic acids encoding the polypeptide(s) present in said biological sample; and (c) comparing the amount and/or concentration of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex determined in said biological sample with the amount and/or concentration of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding MRP8 and/or MRP14 polypeptide(s) determined in said biological sample with the amount and/or concentration of nucleic acids encoding MRP8 and/or MRP14 polypeptide(s) measured in a control sample, wherein the difference in the amount of MRP8 and/or MRP14 polypeptide(s) and/or MRP8/MRP14 protein complex and/or nucleic acids encoding the polypeptide(s) is indicative for the stages of the disease to be diagnosed.

公开(公告)号：WO2003069341A2

公开(公告)日：2003-08-21

申请号：PCT/EP2003/001575

申请日：2003-02-17

Applicant: SWITCH BIOTECH AG ,  SORG, Clemens ,  ROTH, Johannes

Inventor： SORG, Clemens ,  ROTH, Johannes

IPC: G01N33/564

CPC classification number: G01N33/53 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/564 ,  G01N33/6893 ,  G01N2333/4727 ,  G01N2333/52 ,  G01N2800/065

Abstract: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or con­centration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measured in a control sample, wherein the difference in the amount of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide is indicative for the stages of the disease to be diagnosed.

Abstract translation: 本发明涉及一种用于诊断基于标记物CALGRANULIN C的炎性疾病的方法，特别是用于诊断炎性疾病的特定阶段和/或用于确定复发的风险和/或用于区分具有相似症状的疾病的所述方法，所述方法包括 获得待诊断的哺乳动物体液或组织的生物样品的步骤b确定存在于所述生物样品中的CALGRANULIN C多肽和/或编码多肽的核酸的量和/或浓度，c将所述量和/或 CALGRANULIN C多肽的浓度在对照样品中测定的CALGRANULIN C多肽的量和/或浓度确定在所述生物样品中，和/或比较在所述生物样品中测定的编码CALGRANULIN C多肽的核酸的量和/或浓度与 编码CALGRANULIN C p。的核酸的量和/或浓度 在对照样品中测量的双糖，其中CALGRANULIN C多肽和/或编码多肽的核酸的量的差异指示待诊断的疾病的阶段。